Biologics Commonly Used in Cutaneous Crohn's Disease - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Biologics Commonly Used in Cutaneous Crohn's Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn's disease.

  • By

  • Andrea Surnit

  • May 27, 2026

  • 3 min

Share

  • 1

    A retrospective study found that most patients with cutaneous Crohn disease improved after receiving biologic or small-molecule inhibitor therapy.

  • 2

    The study reviewed data from 57 patients, with 81% being female and a mean diagnosis age of 37 years.

  • 3

    Genital involvement was the most common cutaneous presentation, occurring in 44% of patients.

  • 4

    Tumor necrosis factor alpha inhibitors were the most frequently prescribed biologics, used in 85% of treated patients.

  • 5

    The study's limitations include its uncontrolled design and variability in treatment regimens across institutions.

Original Source(s)

Biologics Commonly Used in Cutaneous Crohn's Disease

  • by Andrea Surnit

  • May 27, 2026

Related Content

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

What Parents Need to Know About Moles in Children